Lactamax

Quick links to important sections

Lactamax

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lactamax

Quick Facts

Property Description
Active ingredient Cabergoline
Form Oral tablet (Single-component product)
Pharmacological class Dopamine Agonist, Prolactin Inhibitor
General purpose Reduces elevated prolactin levels
Origin Synthetic compound (Ergoline derivative)

What Type of Medicine is Lactamax (Cabergoline)?

Lactamax is a prescription-only medicine that contains the active substance Cabergoline, and it is classified as both a highly selective Dopamine Agonist and a potent, long-acting Prolactin Inhibitor. This classification highlights its specialized function within the endocrine system. The active ingredient, Cabergoline, is a synthetic compound known chemically as an ergoline derivative. This specific chemical structure is clinically recognized for providing its distinct long duration of action, a property that differentiates it from non-selective analogues.

Composition and Physical Form of Lactamax

The medication is a single-component product administered in the oral tablet dosage form, defining its physical preparation for ingestion. The tablets exclusively contain the active ingredient (Cabergoline), alongside solid pharmaceutical excipients that form the tablet matrix. This structure, utilizing the oral route of administration, ensures a standardized and predictable delivery of Cabergoline into the patient's system. This single-ingredient format is designed specifically to focus on the targeted action of Cabergoline, supporting its use in adult patients who require precise hormonal modulation.

General Purpose: Targeting Prolactin Secretion

The general purpose of Lactamax is to manage issues arising from abnormally high levels of the hormone prolactin by enabling the reduction of prolactin levels. The active substance achieves this through the selective stimulation of D2 dopamine receptors located in the pituitary gland. Activating these receptors results in a powerful and sustained inhibition of prolactin secretion, a mechanism utilized in clinical settings. The foundational role of the medicine is to correct the hormonal imbalance caused by excessive prolactin.

What side effects are possible with Lactamax?

Regulatory Description of Possible Side Effects and Safety Characteristics

The safety profile of Lactamax (Cabergoline) is officially classified by regulatory documents according to the systems affected and the frequency of occurrence. As a Dopamine Agonist, the medicine's effects are documented across multiple physiological domains.

Frequency and System-Organ Classifications

The most frequent adverse reactions, classified as Very Common in regulatory documentation, include those affecting the Nervous System (e.g., headache, dizziness) and the Gastrointestinal System (e.g., nausea). Reactions classified as Common include further effects like constipation, vomiting, asthenia (fatigue), and somnolence (sleepiness).

Classification Examples of Side Effects
Very Common Nausea, Headache, Dizziness
Common Vomiting, Constipation, Asthenia, Somnolence

Serious Adverse Reactions and Safety Constraints

The most significant safety consideration associated with long-term, high-dose exposure involves the risk of fibrotic reactions, which includes pulmonary fibrosis and cardiac valvulopathy (heart valve disease). The official labeling indicates that the risk of these serious reactions is associated with the duration of use.

Time-related safety patterns note that orthostatic hypotension (a drop in blood pressure upon standing) is more likely to be experienced at the initiation of treatment or during a dose-escalation period.

The medicine is contraindicated in patients with anatomical evidence of cardiac valvulopathy or a history of fibrotic disorders. Specific safety considerations require caution for patients with severe hepatic impairment.

Overdose and Emergency Response

The overdose profile of Lactamax (Cabergoline) is officially documented as relating to the consequences of acute dopaminergic over-stimulation, primarily affecting the central nervous and cardiovascular systems. Documented manifestations of an excessive intake may include hallucinations, profound central nervous system effects, and physiological findings such as fainting (syncope) and significant hypotension (low blood pressure).

Condition Requiring Immediate Medical Help Supportive Management & Antidote Status
Collapse or inability to be awakened Treatment is symptomatic and supportive; interventions should prioritize maintaining blood pressure.
Seizure or severe central nervous system changes No specific antidote is known for Cabergoline overdose.
Trouble breathing (respiratory distress) Call emergency services (911) immediately for any of these severe signs.

Official regulatory documents specify that urgent medical help must be sought if the individual exhibits these life-threatening symptoms. The management strategy focuses exclusively on supportive care for the clinical presentation, particularly addressing cardiovascular stability, as the official information clearly states that no specific reversal agent is known to exist. This defined structure dictates all necessary emergency actions.

Therapeutic Uses of Lactamax

Lactamax's primary therapeutic domain is used in situations involving certain distressing symptoms related to physical discomfort, inflammation, and fever. Medications in this pharmacological class are used to help with a wide array of conditions presenting with systemic or localized discomfort.


The medicine is primarily applied in addressing symptom clusters that may become intense or disruptive, such as headaches, muscular aches, toothaches, and menstrual pain. It is also relevant in conditions characterized by periods of heightened symptoms, including the symptomatic management of pain and stiffness associated with various forms of arthritis (like osteoarthritis and rheumatoid arthritis). In clinical settings, Lactamax may assist with reducing fever. The medication is considered relevant for easing symptoms that interfere with daily functioning, providing supportive relief that helps patients cope more steadily with symptom fluctuations.

“It assists with maintaining functional stability during episodes of discomfort.”

Quick Fact: Relief for Physical Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information on Ibuprofen

Eligibility and Restrictions for Use

Who Can and Cannot Use Lactamax?

Eligibility for Lactamax (Cabergoline) is strictly defined by regulatory authorities and is determined by patient history, age, and physiological status.

Absolute Contraindications

Lactamax is contraindicated and must not be used in specific patient populations, primarily those with a history of fibrotic disorders affecting the lungs, heart lining, or abdomen, or those with anatomical evidence of cardiac valvulopathy. The medicine is also prohibited for patients with uncontrolled, post-partum, or pregnancy-induced hypertension (including Pre-eclampsia or Eclampsia). Absolute non-eligibility also applies to individuals with known hypersensitivity to Cabergoline or any other ergot alkaloid.


Age and Conditional Use

Use in subjects under 16 years of age is not established by safety and efficacy data, making the medicine unsuitable for this population. While generally approved for adults, caution is required for older adults and patients with severe hepatic insufficiency, often necessitating consideration of a lower dose for prolonged treatment.

Pregnancy and Lactation

Pregnancy must be excluded before treatment begins, and women must use contraception during treatment and for at least one month after stopping. Lactamax should not be administered to mothers who intend to breastfeed, as it directly acts to inhibit milk production.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define specific interaction patterns for Lactamax (Cabergoline), particularly with medicines affecting dopamine receptors or blood pressure.

Co-administration with Dopamine Antagonists (or D2-Antagonists), such as certain anti-psychotic medicines (e.g., phenothiazines, metoclopramide), is not recommended. These substances may counteract the medicine's prolactin-lowering effect. Concomitant use with other Ergot Derivatives is also restricted.

Pharmacodynamic and Pharmacokinetic Interactions

Category Interacting Substance Regulatory Statement
Pharmacodynamic Antihypertensive Agents Use with caution due to the risk of an additive hypotensive effect, which may result in orthostatic hypotension.
Pharmacokinetic Macrolide Antibiotics These may increase the systemic bioavailability (exposure) of Cabergoline and should be used cautiously.
Metabolism CYP450 System Metabolism is primarily via hydrolysis, with minimal involvement from the Cytochrome P450 enzyme system.

Lactamax administration is preferably taken with meals to improve overall tolerability. The effects of alcohol on the medicine's tolerability are officially listed as unknown.

Specific restrictions exist for certain populations: the medicine is contraindicated in patients with severe hepatic insufficiency due to the risk of substantially increased exposure.

Mechanism of Action

Lactamax modulates the RANKL/OPG axis, a key regulator of bone remodeling. Its primary action involves binding to RANKL (Receptor Activator of Nuclear Factor kappa B Ligand), thereby limiting the availability of RANKL to its receptor, RANK, on the surface of pre-osteoclast cells. This specific molecular interaction inhibits the subsequent RANK/RANKL signaling cascade. The suppression of this pathway reduces the differentiation, maturation, and activation of osteoclasts, which are the cells responsible for bone resorption. Concurrently, Lactamax may influence the expression of Osteoprotegerin (OPG), an endogenous decoy receptor for RANKL produced by osteoblasts. This combined modulation influences the overall ratio of osteoclastogenesis to osteoblast-mediated bone formation. The resulting cellular effect is a decrease in the rate of osteoclast-mediated bone resorption, leading to an alteration in systemic bone remodeling markers.

Dosage and Administration Information

How to Use Lactamax

Lactamax, which contains the active substance Cabergoline, is a prescription-only medicine administered via the oral route in tablet form. Its usage protocol is highly structured and determined by clinical guidelines, focusing on low, slowly titrated doses.


Administration Parameters

Instruction Entity Clinical Administration Parameter
Route of Administration The medication is administered through the oral route in tablet form.
Standard Dosing Schedule The initial dose for hyperprolactinemia is 0.25 mg administered twice weekly.
Titration Interval Dose increases must occur at intervals of no less than 4 weeks, with increments of 0.25 mg twice weekly until the optimal response is achieved.
Maximum Weekly Dose The maximum recommended dose is 1 mg administered twice weekly, totaling 2 mg per week.
Meal Timing The tablets may be taken with or without food. Certain guidelines suggest taking it preferably with food to optimize tolerability.
Hepatic Adjustment Use is cautious in patients with severe hepatic impairment; some guidelines suggest a dose limit of no more than 1 mg per day.
Pediatric Use Safety and efficacy in pediatric patients under 16 years of age have not been established.
Duration and Cessation Therapy may be stopped if serum prolactin levels are maintained as normal for 6 continuous months.

The overall administration protocol is characterized by an infrequent, twice-weekly schedule designed for slow dose escalation. If a scheduled dose is missed, standard protocol indicates the next dose should be taken at the next regularly scheduled time without doubling the dose. This procedural structure defines a long-term treatment course dependent on careful, monthly monitoring and adjustment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has explored the evaluation of this study drug in patients with the target condition. These large-scale, randomized controlled trials (RCTs) investigated whether patient outcomes were affected when compared to a placebo or standard-of-care. The study design included evaluation of short-term study completion rates across the study populations.

The primary focus of these trials was to gather data on the incidence of various endpoints, including time to specific changes in health status and the frequency of reported adverse events. This comprehensive data collection provides the foundation for understanding the drug's profile in controlled settings.


Studies on Drug Behavior and Regimens

Studies included assessment of the drug’s absorption and distribution in the body. These studies concentrated on understanding the movement and effects of the drug within the body. This information, known as pharmacokinetics and pharmacodynamics, helps characterize the drug’s profile.

  • Regimen Outcomes: Several studies evaluated whether the timing of treatment initiation related to different outcomes. Data suggested the potential for variability in outcomes depending on the regimen explored by the researchers.
  • Long-Term Follow-up: One study reported on the return of indicators over the study period, tracking patients for six months following the conclusion of treatment to observe longer-term trends within the controlled research environment.

Important Note on Interpretation

It is essential to remember that the findings of these studies describe outcomes in controlled research settings and do not guarantee individual results. Studies collected data on the drug’s effects on this condition, and this research remains part of the overall body of evidence.

It is appropriate for patients to consult with their doctor or pharmacist to discuss whether this treatment aligns with their specific medical circumstances, considering all available evidence and clinical guidelines.

Frequently Asked Questions (FAQ)

Common questions about Lactamax (FAQ)


Q: What are the approved indications and uses listed in official documents for Lactamax?

Regulatory documents list the medicine's approved uses, which focus on treating conditions associated with hyperprolactinemia (abnormally high prolactin levels). This includes, for example, specific types of menstrual cycle dysfunction and certain hormone-secreting tumors linked to high prolactin.


Q: Is Lactamax available in different strengths or forms (e.g., liquid vs. tablet)?

The medication is supplied exclusively in the oral tablet form and is not available as a liquid. Regulatory documents typically list tablet strengths, which commonly include both 0.25 mg and 0.5 mg tablets.


Q: What is the difference between Lactamax and generic medications for the same condition?

Regulatory bodies define the brand name and its approved generic counterparts as containing the same active ingredient (Cabergoline) and being therapeutically equivalent. This means both versions meet the same rigorous standards for strength, quality, and effectiveness.


Q: Does Lactamax have any documented effect on fertility?

The medicine's effect is often linked to the correction of the hormonal imbalance in women whose hyperprolactinemia causes amenorrhea (absence of menstruation). The medicine is described as correcting the hormonal imbalance associated with the condition.


Q: How quickly does Lactamax typically start to work after the first use?

Regulatory data shows that the prolactin-lowering effect begins relatively quickly, starting approximately 3 hours after a single dose is administered.


Q: What is the expected duration of the beneficial effect of a single dose of Lactamax?

The medicine has a long duration of action. Following a single dose, the prolactin-lowering effect is typically sustained, with the effect lasting up to 7 to 28 days in patients being treated for hyperprolactinemia.


Q: Is it normal to not notice the full effects of Lactamax for several weeks?

Since the medicine is taken on an infrequent, twice-weekly schedule with mandated dose adjustments occurring no more often than every four weeks, the full therapeutic response often requires several weeks or months due to the gradual, low-frequency dose adjustment schedule.


Q: What physical or symptomatic changes indicate that Lactamax is having its intended effect?

The medicine's primary clinical effect is the normalization of prolactin levels. Patient-perceivable indicators that the medicine is working may include the cessation of abnormal milk discharge (galactorrhea) and the return of regular menstrual cycles.


Q: Are there any special tests or monitoring required when starting Lactamax?

Official guidelines describe the need for a comprehensive cardiac evaluation, which often includes an echocardiogram, to assess heart valve status before starting the medicine due to the potential risk of valvulopathy. The protocol also indicates that continuous monitoring of serum prolactin levels is a necessary component of the treatment course.


Q: What should I do if I experience an allergic reaction to Lactamax?

Regulatory information advises that signs of an allergic reaction (hypersensitivity), such as a rash or swelling, warrant immediate attention from a healthcare provider for evaluation. A known hypersensitivity to the active ingredient or other ergot derivatives is listed as an absolute contraindication for using the medicine.


Q: Can Lactamax affect a person's ability to drive or operate machinery?

Official warnings advise patients that the medicine can cause somnolence (sleepiness) or even sudden sleep episodes. Those who experience drowsiness should refrain from driving or operating dangerous machinery, as noted in the product label.


Q: Does Lactamax have a known risk of causing changes in mood or sleep patterns?

Official documentation reports that the medicine may be associated with psychiatric effects, such as depression, anxiety, or aggression. Central nervous system effects are also documented, including somnolence (sleepiness) and insomnia (difficulty sleeping).


Q: Can taking Lactamax cause changes in body weight?

Regulatory documentation indicates that changes in body weight are documented as possible adverse reactions. This includes both weight gain and weight decrease, although these effects are typically reported less frequently than other common side effects.


Q: Do the side effects of Lactamax typically lessen after taking the medication for a while?

Official documents note that side effects are sometimes time-dependent. For instance, orthostatic hypotension (a drop in blood pressure when standing) is most likely to occur at the start of treatment or during dose increases. Conversely, the most serious risks, such as fibrotic reactions, are typically associated with long-term, high-dose exposure.


Q: Are there warnings about using Lactamax if a person has underlying liver or kidney issues?

Official product information states that the medicine is contraindicated or requires caution in individuals with severe liver impairment. Regarding kidney issues, regulatory information advises caution because the pharmacokinetics (how the body handles the drug) have not been fully studied in those with severe kidney failure.


Q: What information is available regarding stopping Lactamax suddenly?

The main outcome noted upon stopping the therapy is the potential for prolactin levels to rise again (rebound hyperprolactinemia). Professional monitoring of prolactin levels is a described component of the cessation protocol.

How should Lactamax be stored and disposed of?

Lactamax (Cabergoline) must be stored and handled according to specific regulatory requirements to maintain the product's stability, as the tablets are sensitive to moisture and heat.

Requirement Category Official Storage Rule
Temperature Store at Controlled Room Temperature, 20 C to 25 C, with excursions permitted up to 30 C (Do not freeze).
Protection Keep the container tightly closed to protect from moisture and light.
Container Dispense and store only in the original container; the desiccant must not be removed.
Safety Must be kept out of the sight and reach of children and pets.
Disposal Dispose of any unused or expired medicine in accordance with local requirements, ideally through a drug take-back program. Do not flush unless the label specifically instructs it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lactamax found in:

A-Z Index: